Adjuvant Therapies for Stage 4 Breast Cancer

Introduction to Adjuvant Therapies

The National Comprehensive Cancer Network recommends adjuvant therapy for patients with stage 4 breast cancer, including endocrine therapy with targeted agents for hormone receptor-positive disease, anti-HER2 therapy for HER2-positive disease, and chemotherapy for triple-negative or rapidly progressing disease 1, 2

For women with HR-positive, HER2-negative metastatic breast cancer, endocrine therapy alone or in combination with targeted agents is the preferred initial approach, as recommended by the National Comprehensive Cancer Network 1
Aromatase inhibitors in combination with CDK4/6 inhibitors have demonstrated improved progression-free survival compared to AI alone and should be considered as first-line therapy, according to the National Comprehensive Cancer Network 1
Premenopausal women should receive adequate ovarian suppression/ablation and then be treated similarly to postmenopausal women, as suggested by the National Comprehensive Cancer Network 1
Patients who progress on or within 12 months of completing adjuvant endocrine therapy are eligible for second-line endocrine therapy either as monotherapy or in combination with a targeted agent, as recommended by the National Comprehensive Cancer Network 1
Options for second-line therapy include fulvestrant with a CDK4/6 inhibitor, fulvestrant with alpelisib for tumors with PIK3CA mutations, everolimus combined with an AI, tamoxifen, or fulvestrant, and monotherapy with fulvestrant, nonsteroidal or steroidal AI, or selective estrogen receptor modulator, according to the National Comprehensive Cancer Network 2

For patients with bone metastases, bisphosphonates or denosumab should be added to systemic therapy, as recommended by the National Comprehensive Cancer Network 1
Recommended agents include pamidronate and zoledronic acid, with denosumab shown to significantly delay time to first skeletal-related event compared to zoledronic acid, according to the National Comprehensive Cancer Network 1

Options for HER2-positive, HR-positive disease include HER2-targeted therapy plus chemotherapy or endocrine therapy in combination with HER2-targeted therapy, as recommended by the National Comprehensive Cancer Network 3
Adding trastuzumab or lapatinib to an AI has demonstrated progression-free survival advantage compared with AI alone, according to the National Comprehensive Cancer Network 3
HER2-targeted therapy in combination with chemotherapy is the standard approach for HER2-positive, HR-negative disease, as recommended by the National Comprehensive Cancer Network 3

Chemotherapy remains the primary systemic treatment option for triple-negative breast cancer, with anthracycline and taxane-based chemotherapy recommended as initial treatment, according to the European Society for Medical Oncology 4

A combined treatment modality based on a multidisciplinary approach is strongly indicated for locally advanced breast cancer, as recommended by the European Society for Medical Oncology 4
Extended adjuvant therapy with aromatase inhibitors for up to 10 years may be considered for node-positive breast cancer, but benefits must be weighed against ongoing side effects, according to the American Society of Clinical Oncology 5

Patients should be monitored every 2-3 months for endocrine therapy or after 2-3 cycles of chemotherapy, with treatment adjusted accordingly, as recommended by the European Society for Medical Oncology 6
Upon progression, patients should be switched to the next line of therapy, according to the National Comprehensive Cancer Network 3

The American College of Surgeons and the National Comprehensive Cancer Network recommend single-agent abemaciclib for heavily pretreated patients with HR-positive, HER2-negative disease, with a median PFS of 6 months and median OS of 22.3 months in the MONARCH 1 trial 7
The National Comprehensive Cancer Network suggests megestrol acetate, estradiol, or androgens as later-line options for HR-positive, HER2-negative disease 7
For HER2-positive, HR-negative disease, the National Comprehensive Cancer Network recommends pertuzumab + trastuzumab + docetaxel as the standard first-line approach, with a median PFS of 18.5 months and a 34% reduction in death risk 7
The FDA-approved trastuzumab biosimilars are appropriate substitutes for HER2-positive disease 7
The National Comprehensive Cancer Network recommends continuing HER2-targeted therapy until progression or unacceptable toxicity, as sequential HER2-targeted therapies remain beneficial 7

The European Society for Medical Oncology recommends chemotherapy as the primary systemic treatment for triple-negative breast cancer, with anthracycline and taxane-based regimens as initial therapy 8

The British Journal of Cancer advises against routine metastatic screening in asymptomatic patients during follow-up, as screening for metastases is not indicated 9
The British Journal of Cancer recommends against relying on tumor markers alone to change treatment, and against using high-dose chemotherapy outside clinical trials 9, 10